Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society

Alexander R. Lyon; Susan Dent; Susannah Stanway; Helena Earl; Christine Brezden-Masley; Alain Cohen-Solal; Carlo G. Tocchetti; Javid J. Moslehi; John D. Groarke; Jutta Bergler-Klein; Vincent Khoo; Li Ling Tan; Markus S. Anker; Stephan von Haehling; Christoph Maack; Radek Pudil; Ana Barac; Paaladinesh Thavendiranathan; Bonnie Ky; Tomas G. Neilan; Yury Belenkov; Stuart D. Rosen; Zaza Iakobishvili; Aaron L. Sverdlov; Ludhmila A. Hajjar; Ariane V.S. Macedo; Charlotte Manisty; Fortunato Ciardiello; Dimitrios Farmakis; Rudolf A. de Boer; Hadi Skouri; Thomas M. Suter; Daniela Cardinale; Ronald M. Witteles; Michael G. Fradley; Joerg Herrmann; Robert F. Cornell; Ashutosh Wechelaker; Michael J. Mauro; Dragana Milojkovic; Hugues de Lavallade; Frank Ruschitzka; Andrew J.S. Coats; Petar M. Seferovic; Ovidiu Chioncel; Thomas Thum; Johann Bauersachs; M. Sol Andres; David J. Wright; Teresa López-Fernández; Chris Plummer; Daniel Lenihan

doi:10.1002/ejhf.1920

Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society

Alexander R. Lyon^*, Susan Dent, Susannah Stanway, Helena Earl, Christine Brezden-Masley, Alain Cohen-Solal, Carlo G. Tocchetti, Javid J. Moslehi, John D. Groarke, Jutta Bergler-Klein, Vincent Khoo, Li Ling Tan, Markus S. Anker, Stephan von Haehling, Christoph Maack, Radek Pudil, Ana Barac, Paaladinesh Thavendiranathan, Bonnie Ky, Tomas G. NeilanYury Belenkov, Stuart D. Rosen, Zaza Iakobishvili, Aaron L. Sverdlov, Ludhmila A. Hajjar, Ariane V.S. Macedo, Charlotte Manisty, Fortunato Ciardiello, Dimitrios Farmakis, Rudolf A. de Boer, Hadi Skouri, Thomas M. Suter, Daniela Cardinale, Ronald M. Witteles, Michael G. Fradley, Joerg Herrmann, Robert F. Cornell, Ashutosh Wechelaker, Michael J. Mauro, Dragana Milojkovic, Hugues de Lavallade, Frank Ruschitzka, Andrew J.S. Coats, Petar M. Seferovic, Ovidiu Chioncel, Thomas Thum, Johann Bauersachs, M. Sol Andres, David J. Wright, Teresa López-Fernández, Chris Plummer, Daniel Lenihan

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

441 Citations (Scopus)

Abstract

This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in collaboration with the International Cardio-Oncology Society presents practical, easy-to-use and evidence-based risk stratification tools for oncologists, haemato-oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities. Baseline risk stratification proformas are presented for oncology patients prior to receiving the following cancer therapies: anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor inhibitors, second and third generation multi-targeted kinase inhibitors for chronic myeloid leukaemia targeting BCR-ABL, multiple myeloma therapies (proteasome inhibitors and immunomodulatory drugs), RAF and MEK inhibitors or androgen deprivation therapies. Applying these risk stratification proformas will allow clinicians to stratify cancer patients into low, medium, high and very high risk of cardiovascular complications prior to starting treatment, with the aim of improving personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies.

Original language	English
Pages (from-to)	1945-1960
Number of pages	16
Journal	European Journal of Heart Failure
Volume	22
Issue number	11
DOIs	https://doi.org/10.1002/ejhf.1920
Publication status	Published - Nov 2020
Externally published	Yes

Bibliographical note

Funding Information:
A.R.L. is supported by the Fondation Leducq Network of Excellence in Cardio-Oncology. C.G.T. is supported by the grant ‘Ricerca di Ateneo Federico II 2017’. A.L.S. is supported by the Heart Foundation of Australia Future Leader Fellowship (Award ID 101918). J.M. is supported by R01 HL141466. R.A.d.B. is supported by the European Research Council (ERC CoG 818715, SECRETE-HF), and furthermore by the Netherlands Heart Foundation (CVON DOSIS, grant 2014-40, CVON SHE-PREDICTS-HF, grant 2017-21; CVON RED-CVD, grant 2017-11; and CVON PREDICT2, grant 2018-30); and the Innovational Research Incentives Scheme program of the Netherlands Organization for Scientific Research (NWO VIDI, grant 917.13.350). C.M. is supported by the German Research Foundation (DFG; SFB-894, TRR-219; Ma 2528/7-1) and the German Ministry of Education and Research (BMBF; 01EO1504).

Funding Information:
A.R.L. has received speaker, advisory board or consultancy fees and/or research grants from Pfizer, Novartis, Servier, Amgen, Takeda, Roche, Janssens‐Cilag Ltd, Clinigen Group, Eli Lily, Eisai, Bristol‐Myers Squibb, Ferring Pharmaceuticals and Boehringer Ingelheim. S.D. has received speaker, advisory board or research funding from Novartis, Eli Lilly, Genetech and Pfizer. S.S. has received speaker, advisory board or consultancy fees from Roche, Clinigen and Eli Lilly. H.E. has received grants from Roche and Sanofi‐Aventis, and advisory board or speaker fees from Daiichi‐Sankyo, AstraZeneca, INTAS Pharmaceuticals, Pfizer, Amgen and Prime Oncology. A.C.S. has received speaker, advisory board or consultancy fees and/or research grants from Novartis, Servier, Amgen, Abbott, Vifor, AstraZeneca, MSD, Roche, Takeda and Bristol‐Myers Squibb. J.M. has served as a consultant for Novartis, Pfizer, Bristol‐Myers Squibb, Takeda, Pharmacyclics, Regeneron, Myokardia, Audentes Pharmaceuticals, AstraZeneca, Deciphera, Ipsen, and Intrexon and has received grant funding from Pfizer and Bristol‐Myers Squibb. J.D.G. receives research funding from Amgen. T.G.N. has received speaker, advisory board or consultancy fees from Parexel, Intrinsic Imaging, Bristol‐Myers Squibb, H3 Biomedicine, Aprea Therapeutics. A.L.S. has received speaker fees, advisory board and/or research grants from Bayer, Biotronik, Novartis and Vifor. B.K. has received consultancy fees from Bristol‐Myers Squibb. C.G.T. received speaking fees from Alere. H.S. received honoraria for presentations from Servier, Novartis, AstraZeneca, Abbott and Boehringer Ingelheim. C.M. has received speak fees from Pfizer. R.F.C. has received advisory board or consultancy fees from Karyopharm Therapeutics, Takeda and Janssen. V.K. has participated in advisory boards, conferences and educational meetings for Accuray, Astellas, Bayer, Janssen and Boston Scientific. T.L.F. has received speaker fees from Janssen, Amgen, Servier, Daiichi‐Sankyo, MSD, and Philips. A.B. serves on DSMB for CTI Biopharma and has received honoraria from Bristol‐Myers Squibb. P.T. has received speaker fees from Boehringer Ingelheim, Takeda, Amgen. M.S.A. has received personal fees from Servier. D.F. has received consultation fees, speaker honoraria and/or travel grants from Abbott, Boehringer Ingelheim, Daiichi‐Sankyo, Menarini, Novartis, Pfizer, Roche and Servier. C.M. has received speaker, advisory board or consultancy fees from Servier, Amgen, Boehringer Ingelheim, Astra, Novartis, Bayer, Berlin Chemie, Bristol‐Myers Squibb, Daiichi‐Sankyo, Pfizer. S.D.R. has received speaker and advisory board consultancy fees from Servier, Novartis and Clinigen Group. M.G.F. has received advisory board fees from Novartis and research funding from Medtronic. Z.I. has received advisory board or speaker fees from Novartis, AstraZeneca, Boehringer Ingelheim, Pfizer, Bayer, Eli Lilly. T.T. is founder and shareholder of Cardior Pharmaceuticals, served in an advisory board of Novo Nordisk and received honoraria from Amicus Therapeutics and Sanofi‐Genzyme. J.B. has received speaker, advisory board or consultancy fees and/or research grants from Novartis, Vifor, Bayer, Servier, Abiomed, Boehringer Ingelheim, Daiichi‐Sankyo, AstraZeneca, CVRx, BMS, Pfizer, MSD, Abbott, Medtronic and Zoll not related to this manuscript. C.P. has received travel expenses and honoraria for speaking at educational meetings or advisory boards from Amgen, Bayer, Celgene, Ferring, Incyte, Novartis, Pfizer and Roche. Conflict of interest:

Funding Information:
A.R.L. is supported by the Fondation Leducq Network of Excellence in Cardio‐Oncology. C.G.T. is supported by the grant ‘Ricerca di Ateneo Federico II 2017’. A.L.S. is supported by the Heart Foundation of Australia Future Leader Fellowship (Award ID 101918). J.M. is supported by R01 HL141466. R.A.d.B. is supported by the European Research Council (ERC CoG 818715, SECRETE‐HF), and furthermore by the Netherlands Heart Foundation (CVON DOSIS, grant 2014‐40, CVON SHE‐PREDICTS‐HF, grant 2017‐21; CVON RED‐CVD, grant 2017‐11; and CVON PREDICT2, grant 2018‐30); and the Innovational Research Incentives Scheme program of the Netherlands Organization for Scientific Research (NWO VIDI, grant 917.13.350). C.M. is supported by the German Research Foundation (DFG; SFB‐894, TRR‐219; Ma 2528/7‐1) and the German Ministry of Education and Research (BMBF; 01EO1504). M.S.A. has received research support from the German Cardiovascular Research Center.

Publisher Copyright:
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/ejhf.1920

Fingerprint

Dive into the research topics of 'Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society'. Together they form a unique fingerprint.

Cite this

Lyon, A. R., Dent, S., Stanway, S., Earl, H., Brezden-Masley, C., Cohen-Solal, A., Tocchetti, C. G., Moslehi, J. J., Groarke, J. D., Bergler-Klein, J., Khoo, V., Tan, L. L., Anker, M. S., von Haehling, S., Maack, C., Pudil, R., Barac, A., Thavendiranathan, P., Ky, B., ... Lenihan, D. (2020). Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. European Journal of Heart Failure, 22(11), 1945-1960. https://doi.org/10.1002/ejhf.1920

Lyon, Alexander R. ; Dent, Susan ; Stanway, Susannah et al. / Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies : a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. In: European Journal of Heart Failure. 2020 ; Vol. 22, No. 11. pp. 1945-1960.

@article{0c57ce14597e4ca39a781117bdf62552,

title = "Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society",

abstract = "This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in collaboration with the International Cardio-Oncology Society presents practical, easy-to-use and evidence-based risk stratification tools for oncologists, haemato-oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities. Baseline risk stratification proformas are presented for oncology patients prior to receiving the following cancer therapies: anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor inhibitors, second and third generation multi-targeted kinase inhibitors for chronic myeloid leukaemia targeting BCR-ABL, multiple myeloma therapies (proteasome inhibitors and immunomodulatory drugs), RAF and MEK inhibitors or androgen deprivation therapies. Applying these risk stratification proformas will allow clinicians to stratify cancer patients into low, medium, high and very high risk of cardiovascular complications prior to starting treatment, with the aim of improving personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies.",

author = "Lyon, {Alexander R.} and Susan Dent and Susannah Stanway and Helena Earl and Christine Brezden-Masley and Alain Cohen-Solal and Tocchetti, {Carlo G.} and Moslehi, {Javid J.} and Groarke, {John D.} and Jutta Bergler-Klein and Vincent Khoo and Tan, {Li Ling} and Anker, {Markus S.} and {von Haehling}, Stephan and Christoph Maack and Radek Pudil and Ana Barac and Paaladinesh Thavendiranathan and Bonnie Ky and Neilan, {Tomas G.} and Yury Belenkov and Rosen, {Stuart D.} and Zaza Iakobishvili and Sverdlov, {Aaron L.} and Hajjar, {Ludhmila A.} and Macedo, {Ariane V.S.} and Charlotte Manisty and Fortunato Ciardiello and Dimitrios Farmakis and {de Boer}, {Rudolf A.} and Hadi Skouri and Suter, {Thomas M.} and Daniela Cardinale and Witteles, {Ronald M.} and Fradley, {Michael G.} and Joerg Herrmann and Cornell, {Robert F.} and Ashutosh Wechelaker and Mauro, {Michael J.} and Dragana Milojkovic and {de Lavallade}, Hugues and Frank Ruschitzka and Coats, {Andrew J.S.} and Seferovic, {Petar M.} and Ovidiu Chioncel and Thomas Thum and Johann Bauersachs and Andres, {M. Sol} and Wright, {David J.} and Teresa L{\'o}pez-Fern{\'a}ndez and Chris Plummer and Daniel Lenihan",

note = "Funding Information: A.R.L. is supported by the Fondation Leducq Network of Excellence in Cardio-Oncology. C.G.T. is supported by the grant {\textquoteleft}Ricerca di Ateneo Federico II 2017{\textquoteright}. A.L.S. is supported by the Heart Foundation of Australia Future Leader Fellowship (Award ID 101918). J.M. is supported by R01 HL141466. R.A.d.B. is supported by the European Research Council (ERC CoG 818715, SECRETE-HF), and furthermore by the Netherlands Heart Foundation (CVON DOSIS, grant 2014-40, CVON SHE-PREDICTS-HF, grant 2017-21; CVON RED-CVD, grant 2017-11; and CVON PREDICT2, grant 2018-30); and the Innovational Research Incentives Scheme program of the Netherlands Organization for Scientific Research (NWO VIDI, grant 917.13.350). C.M. is supported by the German Research Foundation (DFG; SFB-894, TRR-219; Ma 2528/7-1) and the German Ministry of Education and Research (BMBF; 01EO1504). Funding Information: A.R.L. has received speaker, advisory board or consultancy fees and/or research grants from Pfizer, Novartis, Servier, Amgen, Takeda, Roche, Janssens‐Cilag Ltd, Clinigen Group, Eli Lily, Eisai, Bristol‐Myers Squibb, Ferring Pharmaceuticals and Boehringer Ingelheim. S.D. has received speaker, advisory board or research funding from Novartis, Eli Lilly, Genetech and Pfizer. S.S. has received speaker, advisory board or consultancy fees from Roche, Clinigen and Eli Lilly. H.E. has received grants from Roche and Sanofi‐Aventis, and advisory board or speaker fees from Daiichi‐Sankyo, AstraZeneca, INTAS Pharmaceuticals, Pfizer, Amgen and Prime Oncology. A.C.S. has received speaker, advisory board or consultancy fees and/or research grants from Novartis, Servier, Amgen, Abbott, Vifor, AstraZeneca, MSD, Roche, Takeda and Bristol‐Myers Squibb. J.M. has served as a consultant for Novartis, Pfizer, Bristol‐Myers Squibb, Takeda, Pharmacyclics, Regeneron, Myokardia, Audentes Pharmaceuticals, AstraZeneca, Deciphera, Ipsen, and Intrexon and has received grant funding from Pfizer and Bristol‐Myers Squibb. J.D.G. receives research funding from Amgen. T.G.N. has received speaker, advisory board or consultancy fees from Parexel, Intrinsic Imaging, Bristol‐Myers Squibb, H3 Biomedicine, Aprea Therapeutics. A.L.S. has received speaker fees, advisory board and/or research grants from Bayer, Biotronik, Novartis and Vifor. B.K. has received consultancy fees from Bristol‐Myers Squibb. C.G.T. received speaking fees from Alere. H.S. received honoraria for presentations from Servier, Novartis, AstraZeneca, Abbott and Boehringer Ingelheim. C.M. has received speak fees from Pfizer. R.F.C. has received advisory board or consultancy fees from Karyopharm Therapeutics, Takeda and Janssen. V.K. has participated in advisory boards, conferences and educational meetings for Accuray, Astellas, Bayer, Janssen and Boston Scientific. T.L.F. has received speaker fees from Janssen, Amgen, Servier, Daiichi‐Sankyo, MSD, and Philips. A.B. serves on DSMB for CTI Biopharma and has received honoraria from Bristol‐Myers Squibb. P.T. has received speaker fees from Boehringer Ingelheim, Takeda, Amgen. M.S.A. has received personal fees from Servier. D.F. has received consultation fees, speaker honoraria and/or travel grants from Abbott, Boehringer Ingelheim, Daiichi‐Sankyo, Menarini, Novartis, Pfizer, Roche and Servier. C.M. has received speaker, advisory board or consultancy fees from Servier, Amgen, Boehringer Ingelheim, Astra, Novartis, Bayer, Berlin Chemie, Bristol‐Myers Squibb, Daiichi‐Sankyo, Pfizer. S.D.R. has received speaker and advisory board consultancy fees from Servier, Novartis and Clinigen Group. M.G.F. has received advisory board fees from Novartis and research funding from Medtronic. Z.I. has received advisory board or speaker fees from Novartis, AstraZeneca, Boehringer Ingelheim, Pfizer, Bayer, Eli Lilly. T.T. is founder and shareholder of Cardior Pharmaceuticals, served in an advisory board of Novo Nordisk and received honoraria from Amicus Therapeutics and Sanofi‐Genzyme. J.B. has received speaker, advisory board or consultancy fees and/or research grants from Novartis, Vifor, Bayer, Servier, Abiomed, Boehringer Ingelheim, Daiichi‐Sankyo, AstraZeneca, CVRx, BMS, Pfizer, MSD, Abbott, Medtronic and Zoll not related to this manuscript. C.P. has received travel expenses and honoraria for speaking at educational meetings or advisory boards from Amgen, Bayer, Celgene, Ferring, Incyte, Novartis, Pfizer and Roche. Conflict of interest: Funding Information: A.R.L. is supported by the Fondation Leducq Network of Excellence in Cardio‐Oncology. C.G.T. is supported by the grant {\textquoteleft}Ricerca di Ateneo Federico II 2017{\textquoteright}. A.L.S. is supported by the Heart Foundation of Australia Future Leader Fellowship (Award ID 101918). J.M. is supported by R01 HL141466. R.A.d.B. is supported by the European Research Council (ERC CoG 818715, SECRETE‐HF), and furthermore by the Netherlands Heart Foundation (CVON DOSIS, grant 2014‐40, CVON SHE‐PREDICTS‐HF, grant 2017‐21; CVON RED‐CVD, grant 2017‐11; and CVON PREDICT2, grant 2018‐30); and the Innovational Research Incentives Scheme program of the Netherlands Organization for Scientific Research (NWO VIDI, grant 917.13.350). C.M. is supported by the German Research Foundation (DFG; SFB‐894, TRR‐219; Ma 2528/7‐1) and the German Ministry of Education and Research (BMBF; 01EO1504). M.S.A. has received research support from the German Cardiovascular Research Center. Publisher Copyright: {\textcopyright} 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.",

year = "2020",

month = nov,

doi = "10.1002/ejhf.1920",

language = "English",

volume = "22",

pages = "1945--1960",

journal = "European Journal of Heart Failure",

issn = "1388-9842",

publisher = "Wiley-Blackwell",

number = "11",

}

Lyon, AR, Dent, S, Stanway, S, Earl, H, Brezden-Masley, C, Cohen-Solal, A, Tocchetti, CG, Moslehi, JJ, Groarke, JD, Bergler-Klein, J, Khoo, V, Tan, LL, Anker, MS, von Haehling, S, Maack, C, Pudil, R, Barac, A, Thavendiranathan, P, Ky, B, Neilan, TG, Belenkov, Y, Rosen, SD, Iakobishvili, Z, Sverdlov, AL, Hajjar, LA, Macedo, AVS, Manisty, C, Ciardiello, F, Farmakis, D, de Boer, RA, Skouri, H, Suter, TM, Cardinale, D, Witteles, RM, Fradley, MG, Herrmann, J, Cornell, RF, Wechelaker, A, Mauro, MJ, Milojkovic, D, de Lavallade, H, Ruschitzka, F, Coats, AJS, Seferovic, PM, Chioncel, O, Thum, T, Bauersachs, J, Andres, MS, Wright, DJ, López-Fernández, T, Plummer, C & Lenihan, D 2020, 'Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society', European Journal of Heart Failure, vol. 22, no. 11, pp. 1945-1960. https://doi.org/10.1002/ejhf.1920

Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. / Lyon, Alexander R.; Dent, Susan; Stanway, Susannah et al.
In: European Journal of Heart Failure, Vol. 22, No. 11, 11.2020, p. 1945-1960.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies

T2 - a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society

AU - Lyon, Alexander R.

AU - Dent, Susan

AU - Stanway, Susannah

AU - Earl, Helena

AU - Brezden-Masley, Christine

AU - Cohen-Solal, Alain

AU - Tocchetti, Carlo G.

AU - Moslehi, Javid J.

AU - Groarke, John D.

AU - Bergler-Klein, Jutta

AU - Khoo, Vincent

AU - Tan, Li Ling

AU - Anker, Markus S.

AU - von Haehling, Stephan

AU - Maack, Christoph

AU - Pudil, Radek

AU - Barac, Ana

AU - Thavendiranathan, Paaladinesh

AU - Ky, Bonnie

AU - Neilan, Tomas G.

AU - Belenkov, Yury

AU - Rosen, Stuart D.

AU - Iakobishvili, Zaza

AU - Sverdlov, Aaron L.

AU - Hajjar, Ludhmila A.

AU - Macedo, Ariane V.S.

AU - Manisty, Charlotte

AU - Ciardiello, Fortunato

AU - Farmakis, Dimitrios

AU - de Boer, Rudolf A.

AU - Skouri, Hadi

AU - Suter, Thomas M.

AU - Cardinale, Daniela

AU - Witteles, Ronald M.

AU - Fradley, Michael G.

AU - Herrmann, Joerg

AU - Cornell, Robert F.

AU - Wechelaker, Ashutosh

AU - Mauro, Michael J.

AU - Milojkovic, Dragana

AU - de Lavallade, Hugues

AU - Ruschitzka, Frank

AU - Coats, Andrew J.S.

AU - Seferovic, Petar M.

AU - Chioncel, Ovidiu

AU - Thum, Thomas

AU - Bauersachs, Johann

AU - Andres, M. Sol

AU - Wright, David J.

AU - López-Fernández, Teresa

AU - Plummer, Chris

AU - Lenihan, Daniel

N1 - Funding Information: A.R.L. is supported by the Fondation Leducq Network of Excellence in Cardio-Oncology. C.G.T. is supported by the grant ‘Ricerca di Ateneo Federico II 2017’. A.L.S. is supported by the Heart Foundation of Australia Future Leader Fellowship (Award ID 101918). J.M. is supported by R01 HL141466. R.A.d.B. is supported by the European Research Council (ERC CoG 818715, SECRETE-HF), and furthermore by the Netherlands Heart Foundation (CVON DOSIS, grant 2014-40, CVON SHE-PREDICTS-HF, grant 2017-21; CVON RED-CVD, grant 2017-11; and CVON PREDICT2, grant 2018-30); and the Innovational Research Incentives Scheme program of the Netherlands Organization for Scientific Research (NWO VIDI, grant 917.13.350). C.M. is supported by the German Research Foundation (DFG; SFB-894, TRR-219; Ma 2528/7-1) and the German Ministry of Education and Research (BMBF; 01EO1504). Funding Information: A.R.L. has received speaker, advisory board or consultancy fees and/or research grants from Pfizer, Novartis, Servier, Amgen, Takeda, Roche, Janssens‐Cilag Ltd, Clinigen Group, Eli Lily, Eisai, Bristol‐Myers Squibb, Ferring Pharmaceuticals and Boehringer Ingelheim. S.D. has received speaker, advisory board or research funding from Novartis, Eli Lilly, Genetech and Pfizer. S.S. has received speaker, advisory board or consultancy fees from Roche, Clinigen and Eli Lilly. H.E. has received grants from Roche and Sanofi‐Aventis, and advisory board or speaker fees from Daiichi‐Sankyo, AstraZeneca, INTAS Pharmaceuticals, Pfizer, Amgen and Prime Oncology. A.C.S. has received speaker, advisory board or consultancy fees and/or research grants from Novartis, Servier, Amgen, Abbott, Vifor, AstraZeneca, MSD, Roche, Takeda and Bristol‐Myers Squibb. J.M. has served as a consultant for Novartis, Pfizer, Bristol‐Myers Squibb, Takeda, Pharmacyclics, Regeneron, Myokardia, Audentes Pharmaceuticals, AstraZeneca, Deciphera, Ipsen, and Intrexon and has received grant funding from Pfizer and Bristol‐Myers Squibb. J.D.G. receives research funding from Amgen. T.G.N. has received speaker, advisory board or consultancy fees from Parexel, Intrinsic Imaging, Bristol‐Myers Squibb, H3 Biomedicine, Aprea Therapeutics. A.L.S. has received speaker fees, advisory board and/or research grants from Bayer, Biotronik, Novartis and Vifor. B.K. has received consultancy fees from Bristol‐Myers Squibb. C.G.T. received speaking fees from Alere. H.S. received honoraria for presentations from Servier, Novartis, AstraZeneca, Abbott and Boehringer Ingelheim. C.M. has received speak fees from Pfizer. R.F.C. has received advisory board or consultancy fees from Karyopharm Therapeutics, Takeda and Janssen. V.K. has participated in advisory boards, conferences and educational meetings for Accuray, Astellas, Bayer, Janssen and Boston Scientific. T.L.F. has received speaker fees from Janssen, Amgen, Servier, Daiichi‐Sankyo, MSD, and Philips. A.B. serves on DSMB for CTI Biopharma and has received honoraria from Bristol‐Myers Squibb. P.T. has received speaker fees from Boehringer Ingelheim, Takeda, Amgen. M.S.A. has received personal fees from Servier. D.F. has received consultation fees, speaker honoraria and/or travel grants from Abbott, Boehringer Ingelheim, Daiichi‐Sankyo, Menarini, Novartis, Pfizer, Roche and Servier. C.M. has received speaker, advisory board or consultancy fees from Servier, Amgen, Boehringer Ingelheim, Astra, Novartis, Bayer, Berlin Chemie, Bristol‐Myers Squibb, Daiichi‐Sankyo, Pfizer. S.D.R. has received speaker and advisory board consultancy fees from Servier, Novartis and Clinigen Group. M.G.F. has received advisory board fees from Novartis and research funding from Medtronic. Z.I. has received advisory board or speaker fees from Novartis, AstraZeneca, Boehringer Ingelheim, Pfizer, Bayer, Eli Lilly. T.T. is founder and shareholder of Cardior Pharmaceuticals, served in an advisory board of Novo Nordisk and received honoraria from Amicus Therapeutics and Sanofi‐Genzyme. J.B. has received speaker, advisory board or consultancy fees and/or research grants from Novartis, Vifor, Bayer, Servier, Abiomed, Boehringer Ingelheim, Daiichi‐Sankyo, AstraZeneca, CVRx, BMS, Pfizer, MSD, Abbott, Medtronic and Zoll not related to this manuscript. C.P. has received travel expenses and honoraria for speaking at educational meetings or advisory boards from Amgen, Bayer, Celgene, Ferring, Incyte, Novartis, Pfizer and Roche. Conflict of interest: Funding Information: A.R.L. is supported by the Fondation Leducq Network of Excellence in Cardio‐Oncology. C.G.T. is supported by the grant ‘Ricerca di Ateneo Federico II 2017’. A.L.S. is supported by the Heart Foundation of Australia Future Leader Fellowship (Award ID 101918). J.M. is supported by R01 HL141466. R.A.d.B. is supported by the European Research Council (ERC CoG 818715, SECRETE‐HF), and furthermore by the Netherlands Heart Foundation (CVON DOSIS, grant 2014‐40, CVON SHE‐PREDICTS‐HF, grant 2017‐21; CVON RED‐CVD, grant 2017‐11; and CVON PREDICT2, grant 2018‐30); and the Innovational Research Incentives Scheme program of the Netherlands Organization for Scientific Research (NWO VIDI, grant 917.13.350). C.M. is supported by the German Research Foundation (DFG; SFB‐894, TRR‐219; Ma 2528/7‐1) and the German Ministry of Education and Research (BMBF; 01EO1504). M.S.A. has received research support from the German Cardiovascular Research Center. Publisher Copyright: © 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

PY - 2020/11

Y1 - 2020/11

N2 - This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in collaboration with the International Cardio-Oncology Society presents practical, easy-to-use and evidence-based risk stratification tools for oncologists, haemato-oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities. Baseline risk stratification proformas are presented for oncology patients prior to receiving the following cancer therapies: anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor inhibitors, second and third generation multi-targeted kinase inhibitors for chronic myeloid leukaemia targeting BCR-ABL, multiple myeloma therapies (proteasome inhibitors and immunomodulatory drugs), RAF and MEK inhibitors or androgen deprivation therapies. Applying these risk stratification proformas will allow clinicians to stratify cancer patients into low, medium, high and very high risk of cardiovascular complications prior to starting treatment, with the aim of improving personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies.

AB - This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in collaboration with the International Cardio-Oncology Society presents practical, easy-to-use and evidence-based risk stratification tools for oncologists, haemato-oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities. Baseline risk stratification proformas are presented for oncology patients prior to receiving the following cancer therapies: anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor inhibitors, second and third generation multi-targeted kinase inhibitors for chronic myeloid leukaemia targeting BCR-ABL, multiple myeloma therapies (proteasome inhibitors and immunomodulatory drugs), RAF and MEK inhibitors or androgen deprivation therapies. Applying these risk stratification proformas will allow clinicians to stratify cancer patients into low, medium, high and very high risk of cardiovascular complications prior to starting treatment, with the aim of improving personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies.

UR - http://www.scopus.com/inward/record.url?scp=85089099624&partnerID=8YFLogxK

U2 - 10.1002/ejhf.1920

DO - 10.1002/ejhf.1920

M3 - Article

C2 - 32463967

AN - SCOPUS:85089099624

SN - 1388-9842

VL - 22

SP - 1945

EP - 1960

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

IS - 11

ER -

Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. European Journal of Heart Failure. 2020 Nov;22(11):1945-1960. doi: 10.1002/ejhf.1920